EBS Technologies | Updates

By Team EBS Technologies

Why Earlybird Invested in EBS Technologies



Dear Companists,

After introducing one of our investors, the High-Tech Gründerfonds (HTGF), last week, we would now like to provide you with some details on another investor, Earlybird, which invested in EBS Technologies in 2009. Unlike the HTGF, Earlybird is a private-sector venture capital company with considerable expertise in the medical technology sector.


About Earlybird

Earlybird is a venture capital company focusing on high-tech companies. More specifically, Earlybird focuses on investments during the early stages of company development. Earlybird provides founders not only with financial means, but also with access to an international network and to the capital market.

Since its foundation in 1997, Earlybird has started funds with a total volume of over €700m (USD 900m) and has invested in more than 100 companies.

Many of these companies have produced significant technological and economic innovation and have realized excellent values during IPOs and company sales.

Earlybird supports and empowers European companies on their way toward international and global success. The current portfolio consists of 29 companies from various sectors.


Reasons for Earlybird's Investment

Thom Rasche, medical technology portfolio manager at Earlybird, says the following about the investment in EBS:

 "Earlybird invested in EBS after an in-depth analysis. The neuromodulation market is experiencing rapid growth. Today, doctors mainly use invasive methods that are applied directly within the brain (e.g., for treating Parkinson's disease). Thus, technological innovations in this area focus on precise brain stimulation in order to increase efficacy. Recent research, however, shows that in addition to invasive methods, non-invasive stimulation methods (i.e., methods outside the brain) are increasingly used. In this context, it is important to consider the exact type of stimulation. EBS is the first and only company that adapts stimulation to each individual patient's needs after analyzing the EEG (the brain activity) and that is thus able to offer highly individualized therapy. We are convinced that the stimulation method is most likely more important than the stimulation site. Indeed, clinical trials confirm our hypothesis, so we are more convinced than ever of EBS Technologies today."


Best regards,

The EBS Technologies team


Only registered Companists can comment. Please log in to leave a comment.


Investments in startups and growth companies offer great opportunities, but they are risk investments. In the worst case, the entire investment amount may be lost. Consequently, investments in startups or growth companies are unsuitable for retirement plans. However, there is no obligation to make further contributions. Investors can minimize their risk by diversifying the amount they invest in startups and growth companies and not investing the entire amount in one startup or growth company. Professional investors often follow this strategy because it causes the risk to be distributed among several investments. In this way, successful investments can balance other less successful investments.

The shares of the investors on Companisto are subordinated profit-participating loans (partiarische Nachrangdarlehen). Such loans are shares in a business with similar characteristics as equity. If the company becomes insolvent or is liquidated, the claims of the investors (Companists) – just like those of all other shareholders of the company – will be satisfied from the assets in the insolvency or the assets in liquidation only after the claims of all other external creditors have been satisfied. Thus, Companists are treated like any other shareholder of the company during insolvency or liquidation proceedings.

The company information published on the Companisto website is provided solely by the companies. The projections made by the companies do not guarantee successful development of the company in the future. Consequently, investments in startups and growth companies are suitable only for those investors who can cope with the risk of a total loss of the capital invested. Investors make their own independent investment decisions and bear all risks themselves.

The investments are provided and issued by the individual companies. Companisto is neither the provider nor the issuer of the investments, but solely the internet service platform.

€ 258,825




3.67 %

Share Offered

Please note
The acquisition of the offered securities and investments is associated with considerable risks and can lead to the complete loss of the invested assets. The expected yield is not guaranteed and may be lower. Whether it is a security or an asset investment can be seen in the description of the investment opportunity.
Contact Us
If you have any questions about investing on Companisto, please contact our service team:

Toll-free phone number for investors calling from Germany:
0800 - 100 267 0

Companisto investors hotline:
+49(0)30 - 346 491 493

We are available Monday through Friday between 9 a.m. – 6 p.m.

For companies
Apply for financing Investment Model FAQ for Companies
Investor Support